These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10459993)

  • 1. Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation.
    Nordesjö-Haglund G; Lönnqvist B; Lindberg G; Hellström-Lindberg E
    Lancet; 1999 Mar; 353(9155):846. PubMed ID: 10459993
    [No Abstract]   [Full Text] [Related]  

  • 2. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation.
    Brand RE; DiBaise JK; Quigley EM; Gobar LS; Harmon KS; Lynch JC; Bierman PJ; Bishop MR; Tarantolo SR
    Lancet; 1998 Dec 19-26; 352(9145):1985. PubMed ID: 9872252
    [No Abstract]   [Full Text] [Related]  

  • 3. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric myoelectrical activity and its relationship to the development of nausea and vomiting after intensive chemotherapy and autologous stem cell transplantation.
    DiBaise JK; Brand RE; Lyden E; Tarantolo SR; Quigley EM
    Am J Gastroenterol; 2001 Oct; 96(10):2873-81. PubMed ID: 11693320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
    Jacobse J; Mensink H; van der Stoep-Yap MYEC; Kollen WJW; Bresters D; Bredius RGM
    Bone Marrow Transplant; 2018 Oct; 53(10):1372-1374. PubMed ID: 29795419
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative management of nausea and vomiting.
    Singleton G
    Aust Fam Physician; 2007 Sep; 36(9):733-4. PubMed ID: 17885708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of dimetpramid for the prevention and treatment of neurotoxic reactions during radio- and chemotherapy of lymphogranulomatosis].
    Rakhmilevich BM; Simbirtseva LP; Varshamov IuL; Shagoian MG; Legeza VI
    Med Radiol (Mosk); 1983 Jan; 28(1):16-8. PubMed ID: 6827928
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
    Eisenberg S; Wickline M; Linenberger M; Gooley T; Holmberg L
    Oncol Nurs Forum; 2013 May; 40(3):285-92. PubMed ID: 23615140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the hospital pharmacist in the management of chemotherapy-induced nausea and vomiting].
    Breton D; Jandard V; Cauet A; Paillet M; Galvez O; Faure A; Camus G; Beltrando X; Rimlinger H; Hervouet M; Margery J; Bohand X; Vaylet F
    J Pharm Belg; 2011 Jun; (2):46-50. PubMed ID: 21823442
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain.
    Sutton IR; Daeninck P
    J Support Oncol; 2006; 4(10):531-5. PubMed ID: 17136871
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting.
    Bui NB; Marit G; Hoerni B
    Cancer Treat Rep; 1982 Dec; 66(12):2107-8. PubMed ID: 7139655
    [No Abstract]   [Full Text] [Related]  

  • 16. [Models, projects of health participation].
    Scurti V; Sichetti D; Valerio M
    Assist Inferm Ric; 2005; 24(4):204-8. PubMed ID: 16550700
    [No Abstract]   [Full Text] [Related]  

  • 17. Metoclopramide therapy for chemotherapy -- induced nausea and vomiting.
    Paice JA
    Oncol Nurs Forum; 1983; 10(3):28-31. PubMed ID: 6553903
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicinal plants as antiemetics in the treatment of cancer: a review.
    Haniadka R; Popouri S; Palatty PL; Arora R; Baliga MS
    Integr Cancer Ther; 2012 Mar; 11(1):18-28. PubMed ID: 21821652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Appetite loss, nausea, vomiting].
    Sakamaki S
    Nihon Rinsho; 2007 Jan; 65(1):69-75. PubMed ID: 17233418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nausea and vomiting in chemotherapy].
    Giacchetti S; Imbeaux PH; Alby N; Aguerri MF
    Rev Infirm; 1992 Feb; 42(4):63-5. PubMed ID: 1316631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.